Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
Bayer picks Kumquat for $1.3B KRAS collaboration
Bayer has tapped Kumquat for a juicy opportunity, committing up to $1.3 billion to bag a KRAS G12D inhibitor that is on the cusp of the clinic.
Nick Paul Taylor
Aug 12, 2025 6:29am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
BridgeBio's cancer spinout backs SPAC as path to Nasdaq
Feb 28, 2025 9:25am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Aug 30, 2024 9:12am
